Immunicum to present at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting November 11 - 13
September 19 2016 - 2:45AM
Gothenburg, Sweden,
September 19, 2016. Immunicum AB (publ), a biopharmaceutical
company pursuing to develop sophisticated, safe and efficient
therapeutic cancer treatments with powerful and long lasting immune
responses, today announced that it will present data from its
INTUVAX - HCC I/II clinical study at the Society for Immunotherapy
of Cancer (SITC) 31st Annual
Meeting.
SITC has accepted Immunicum's poster containing
clinical data from INTUVAX - HCC I/II for presentation at the SITC
31st Annual
Meeting, to be held November 11-13, 2016 in National Harbor,
Maryland, USA. Alex Karlsson-Parra, Immunicum's Chief Scientific
Officer, will present the poster titled "Intratumorally injected
pro-inflammatory allogeneic dendritic cells as immune enhancers - a
phase I/II study in patients with advanced hepatocellular
carcinoma".
- SITC's acceptance is yet another prestigious
marker of the scientific interest in INTUVAX and our clinical data.
We also plan to give our next clinical data update on the HCC study
in connection to the SITC meeting, says Jamal El-Mosleh, CEO of
Immunicum.
For more information, please
contact:
Jamal El-Mosleh, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
E-mail: jamal.el-mosleh@immunicum.com
About Immunicum AB
(publ)
Immunicum AB (publ) develops cancer immune primers for the
treatment of
tumor diseases. A phase II clinical trial for the Company's most
advanced
product - INTUVAX® against
kidney cancer - has been initiated. The project
portfolio contains additional clinical phase I/II studies in liver
cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on
First North Premier. www.immunicum.se
The company's Certified Adviser is Redeye
AB
Ph: + 46 8 545 013 31
www.redeye.se
The information in this press
release is disclosed pursuant to the EU Market Abuse Regulation.
The information was released for public disclosure through the
agency of the company's contact person on September 19, 2016 at
08.45 CET
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024